CA2848118C - Endostatin mutants with mutations at atp binding sites - Google Patents

Endostatin mutants with mutations at atp binding sites Download PDF

Info

Publication number
CA2848118C
CA2848118C CA2848118A CA2848118A CA2848118C CA 2848118 C CA2848118 C CA 2848118C CA 2848118 A CA2848118 A CA 2848118A CA 2848118 A CA2848118 A CA 2848118A CA 2848118 C CA2848118 C CA 2848118C
Authority
CA
Canada
Prior art keywords
mutant
seq
amino acid
activity
atp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2848118A
Other languages
English (en)
French (fr)
Other versions
CA2848118A1 (en
Inventor
Yongzhang Luo
Peng Liu
Xinan Lu
Yang Chen
Yan Fu
Guodong Chang
Daifu ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of CA2848118A1 publication Critical patent/CA2848118A1/en
Application granted granted Critical
Publication of CA2848118C publication Critical patent/CA2848118C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2848118A 2011-09-09 2012-09-10 Endostatin mutants with mutations at atp binding sites Active CA2848118C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201110280441 2011-09-09
CN201110280441.8 2011-09-09
PCT/CN2012/081210 WO2013034116A1 (zh) 2011-09-09 2012-09-10 对atp结合位点进行突变的血管内皮抑制素突变体

Publications (2)

Publication Number Publication Date
CA2848118A1 CA2848118A1 (en) 2013-03-14
CA2848118C true CA2848118C (en) 2023-09-05

Family

ID=47831548

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2848118A Active CA2848118C (en) 2011-09-09 2012-09-10 Endostatin mutants with mutations at atp binding sites

Country Status (9)

Country Link
US (1) US10647968B2 (cg-RX-API-DMAC10.html)
EP (1) EP2754718B1 (cg-RX-API-DMAC10.html)
JP (1) JP6336389B2 (cg-RX-API-DMAC10.html)
CN (2) CN117987505A (cg-RX-API-DMAC10.html)
AU (1) AU2012306826B2 (cg-RX-API-DMAC10.html)
CA (1) CA2848118C (cg-RX-API-DMAC10.html)
IL (1) IL231419A0 (cg-RX-API-DMAC10.html)
RU (1) RU2014113924A (cg-RX-API-DMAC10.html)
WO (1) WO2013034116A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926933B (zh) * 2014-03-19 2018-09-07 北京仁和天通生物科技有限公司 Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用
CN107148277B (zh) * 2014-11-03 2022-03-22 清华大学 一种抑制脂肪细胞分化和胰岛素耐受的药物
JP6896636B2 (ja) * 2015-02-13 2021-06-30 清華大学Ｔｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ 組換えタンパク質薬の分子設計
CN110317264B (zh) * 2015-11-10 2022-10-11 孙嘉琳 一种抗肿瘤蛋白内皮抑素的衍生物
WO2018086603A1 (zh) * 2016-11-10 2018-05-17 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用
WO2019024814A1 (zh) * 2017-07-30 2019-02-07 清华大学 抑制dna依赖蛋白激酶催化亚基的药物
CN114645025B (zh) * 2022-04-13 2023-12-22 南开大学 一种人源atp合成酶的纯化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029856A1 (en) * 1997-12-08 1999-06-17 Beth Israel Deaconess Medical Center Restin and methods of use thereof
AU4982200A (en) * 1999-05-06 2000-11-21 Burnham Institute, The Antiangiogenic endostatin peptides, endostatin variants and methods of use
CN1237072C (zh) * 2000-05-22 2006-01-18 烟台荣昌生物工程有限公司 生产内皮抑制素的方法
JP4511108B2 (ja) * 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN101143894A (zh) * 2007-06-22 2008-03-19 中国药科大学 高效抑制血管生成多肽及其物理化学修饰方法和应用
EP2270055A4 (en) * 2008-04-04 2011-06-29 Procell Therapeutics Inc CELLPERMEABLE RECOMBINANT ENDOSTATINE PROTEIN, POLYNUCLEOTIDE FOR ITS CODING AND ANTICIPATED PREPARATION WITH THE PROTEIN AS AN ACTIVE SUBSTANCE
CN101256139A (zh) * 2008-04-18 2008-09-03 山东先声麦得津生物制药有限公司 一种血管内皮抑制素生物活性的检测方法
CN101890155B (zh) * 2010-05-25 2012-07-25 江苏先声药物研究有限公司 一种药物组合物及其应用

Also Published As

Publication number Publication date
JP6336389B2 (ja) 2018-06-06
CN108291248B (zh) 2024-03-08
JP2014531897A (ja) 2014-12-04
IL231419A0 (en) 2014-04-30
AU2012306826B2 (en) 2018-01-04
EP2754718A1 (en) 2014-07-16
US20140308263A1 (en) 2014-10-16
CN117987505A (zh) 2024-05-07
AU2012306826A1 (en) 2014-04-03
WO2013034116A1 (zh) 2013-03-14
HK1251864A1 (zh) 2019-04-26
US20150197733A9 (en) 2015-07-16
RU2014113924A (ru) 2015-10-20
CA2848118A1 (en) 2013-03-14
CN108291248A (zh) 2018-07-17
US10647968B2 (en) 2020-05-12
EP2754718B1 (en) 2017-12-13
EP2754718A4 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
US10647968B2 (en) Endostatin mutants with mutations at ATP binding sites
CN100400657C (zh) 磷酸激酶及其应用
CN102121023B (zh) 突变型人纤溶酶原kringle5及其制备方法及应用
KR20110136825A (ko) 미락 단백질
ES2944889T3 (es) Variantes de alfa-galactosidasa humana
JP2021534776A (ja) リコンビナントタンパク質変異体
KR20210035806A (ko) 가용화된 아피라제, 방법 및 용도
CN107530407A (zh) 丙酰辅酶a羧化酶组合物及其用途
CN114588273B (zh) 一种抑制肿瘤免疫逃逸多肽的应用
CN102311493B (zh) 一种抑制端粒酶活性的肽及其制备方法和应用
CN101643511B (zh) 抑制端粒酶活性的融合蛋白、其制备及应用
CN113717278B (zh) 一种肿瘤抑制肽
CN116057071B (zh) 重组灵芝免疫调节蛋白新突变体及其应用
KR101123130B1 (ko) Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
CN1284797C (zh) 人重组组织因子的构建表达、纯化方法及其应用
HK1194771A (en) Vascular endothelial myostatin mutant that mutates at atp binding sites
HK1194771B (en) Vascular endothelial myostatin mutant that mutates at atp binding sites
CN103889435A (zh) 用于增加胰岛素敏感性和治疗糖尿病的方法
CN109182341B (zh) 一种抗肿瘤蛋白质及其应用
WO2023108666A1 (zh) 一类靶向covid-19病毒s蛋白的超高亲和力小蛋白及用途
CN1952129B (zh) Angptl4缺失突变体及其应用
CN115521360B (zh) 特异性结合Sestrin2蛋白的多肽及其在消化道癌治疗中的应用
CN111808938A (zh) Atp6v0d2用于动脉粥样硬化的早期诊断或疗效监控
RU2791992C2 (ru) Солюбилизированные апиразы, способы и применение
HK1251864B (en) Vascular endothelial myostatin mutant that mutates at atp binding sites

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140307

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240823

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240823

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250907

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250907